MarketPeel
Insider Trading Intelligence
ER

Esther Rajavelu

SPRO
CFO & CBO · SPERO THERAPEUTICS, INC. · CIK 0001903716
FILING MIX · LIFETIME53%/47%
BUYS
9
SELLS
8
TOTAL VALUE
$476.0K
COMPANIES
2
ACTIVE SINCE
Jan 2022
HOLDINGS NOW
1,146,851
AVG SELL PX
$2.04
TRADE KIND
SHOWING 17 / 17
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
8 backtested trades · 8 horizons · 18 pending
Forward-return performance of every backtestable P/S trade by Esther Rajavelu, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d8+75.00%-2.49%-0.28%-2.21%-1.57%
14d8+75.00%-3.70%+0.01%-3.71%-4.79%
30d8+75.00%-4.25%-0.67%-6.06%-6.49%
60d8+50.00%-5.95%-3.15%-2.79%-7.20%
90d8(1 pending)+57.14%-12.48%+1.76%-14.24%-7.50%
180d8(4 pending)+50.00%+12.34%+0.74%+11.60%-27.95%
1y8(5 pending)+0.00%+112.14%+12.91%+99.22%+74.42%
2y8(8 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SPRO · 986,851 shares · as of May 4, 2026
0279,613559,225838,8381,118,450202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 9 buys / 8 sellsCOVERAGE · 18 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SPRO
SPERO THERAPEUTICS, INC.
SALE
See Remarks
25,240$2.51$63.4K986,851May 4, 2026Feb 9, 2026View →
SPRO
SPERO THERAPEUTICS, INC.
SALE
See Remarks
50,816$2.36$119.9K1,012,091Feb 6, 2026Feb 9, 2026View →
SPRO
SPERO THERAPEUTICS, INC.
SALE
See Remarks
37,101$2.36$87.6K1,062,907Feb 6, 2026Feb 9, 2026View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
249,0001,118,450Feb 2, 2026Feb 4, 2026View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
498,000498,000Feb 2, 2026Feb 4, 2026View →
SPRO
SPERO THERAPEUTICS, INC.
SALE
See Remarks
18,442$2.20$40.6K1,100,008Feb 2, 2026Feb 4, 2026View →
SPRO
SPERO THERAPEUTICS, INC.
SALE
See Remarks
40,270$2.37$95.4K869,450Nov 7, 2025Nov 12, 2025View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
185,000909,720May 2, 2025May 6, 2025View →
SPRO
SPERO THERAPEUTICS, INC.
SALE
CFO & CBO
20,689$0.78$16.1K724,720Feb 5, 2025Feb 5, 2025View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000745,409Feb 3, 2025Feb 5, 2025View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
266,139645,409Feb 3, 2025Feb 5, 2025View →
SPRO
SPERO THERAPEUTICS, INC.
SALE
CFO & CBO
17,245$1.30$22.4K379,270Nov 8, 2024Nov 12, 2024View →
SPRO
SPERO THERAPEUTICS, INC.
SALE
CFO & CBO
23,351$1.31$30.6K396,515Nov 7, 2024Nov 12, 2024View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
119,866419,866Feb 1, 2024Feb 5, 2024View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300,000300,000Nov 13, 2023Nov 15, 2023View →
FULC
FULCRUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
160,000160,000Feb 9, 2023Feb 13, 2023View →
FULC
FULCRUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Jan 3, 2022Jan 10, 2022View →
Other insiders · SPRO
Loading peer insiders…
About this filer
CIK 0001903716
ROLE
CFO & CBO
PRIMARY
SPRO
COMPANIES
2
ACTIVE SINCE
Jan 2022
MARKETPEEL · /INSIDER/0001903716DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback